Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

Metastatic Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:
A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). This study aims to explore whether blockade of Transforming Growth Factor β (TGFβ) in combination with gemcitabine/nab-paclitaxel can reduce fibrosis in PDAC, restore chemo-sensitivity and ultimately lead to improvements in overall survival (OS) and other clinically relevant outcomes.

Clinical Trial Description

This is a randomized, double-blind, multicenter two-arm, phase III study that has two parts: - Safety run-in part: An open-label safety run-in part will be conducted to confirm recommended phase 3 dose (RP3D) of NIS793 in combination with gemcitabine and nab-paclitaxel. Up to approximately 10 participants will be enrolled at each dose level to achieve at least 6 evaluable participants; however, if the starting dose is not recommended and a lower dose level is tested, 10 additional participants will be enrolled. The decision to open the randomized part will be based on dose confirmation and available safety, relevant PK, and other relevant data from run-in part - Randomized part: Enrolled participants will be randomized to the two treatment arms. The study treatment will be administered as a 28-day treatment cycle. Participants will be treated until unacceptable toxicity, disease progression per RECIST 1.1, withdrawal of consent or any other condition of treatment discontinuation specified in the protocol. Note: As of 07-Jul-2023, treatment with NIS793/placebo was stopped. The trial was unblinded and study participants were allowed to continue with standard of care (SoC) chemotherapy (gemcitabine+ nab-paclitaxel) per investigator assessment. ;

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Metastatic Pancreatic Ductal Adenocarcinoma

Clinical Trial Details

NCT number	NCT04935359
Study type	Interventional
Source	Novartis
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	September 30, 2021
Completion date	June 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05095064` - Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan
Active, not recruiting	`NCT05039177` - A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies	Phase 1/Phase 2
Recruiting	`NCT04888312` - Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients	Phase 1/Phase 2
Active, not recruiting	`NCT04390763` - Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	Phase 2
Not yet recruiting	`NCT06206876` - FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma	Phase 1
Recruiting	`NCT05642962` - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 1/Phase 2
Completed	`NCT02501902` - Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC	Phase 1
Active, not recruiting	`NCT04581343` - A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients	Phase 1
Completed	`NCT02558894` - Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma	Phase 2
Terminated	`NCT02732938` - Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients	Phase 2
Recruiting	`NCT05472259` - A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)	Phase 2
Recruiting	`NCT02600949` - Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer	Phase 1
Recruiting	`NCT05630183` - A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer	Phase 2
Completed	`NCT02583477` - Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma	Phase 1/Phase 2
Terminated	`NCT04329949` - Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3
Terminated	`NCT02101021` - Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3
Recruiting	`NCT05685602` - CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer	Phase 1
Completed	`NCT04990037` - A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma	Phase 1
Terminated	`NCT03331640` - A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy	Phase 2
Recruiting	`NCT04150042` - SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells	Phase 1